PTC Therapeutics, Inc. announced that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.52 USD | -1.14% | +0.44% | +32.51% |
May. 24 | Ptc Therapeutics Insider Sold Shares Worth $764,800, According to a Recent SEC Filing | MT |
May. 21 | Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.51% | 2.8B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+1.14% | 22.78B | |
-10.95% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- PTCT Stock
- News PTC Therapeutics, Inc.
- PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza